| |
 |
Editorial [Hot topic: The Hypoxia-Inducible Factor (HIF) Pathway as a Target for Prevention and Treatment of Clinical Manifestations (Executive Editor: Thomas Kietzmann)]
|
| |
|
pp.3837-3838 (2) Author: Thomas Kietzmann
|
| |
|
|
| |
|
HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
|
| |
|
pp.3839-3843 (5) Author: G. L. Semenza
|
| |
|
|
| |
|
Regulation of HIF-1α at the Transcriptional Level
|
| |
|
pp.3844-3852 (9) Author: Agnes Gorlach
|
| |
|
|
| |
|
Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
|
| |
|
pp.3853-3860 (8) Authors: Stefanie Galban, Myriam Gorospe
|
| |
|
|
| |
|
Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
|
| |
|
pp.3861-3866 (6) Authors: Meredith E. Crosby, Cecilia M. Devlin, Peter M. Glazer, George A. Calin, Mircea Ivan
|
| |
|
|
| |
|
Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
|
| |
|
pp.3867-3877 (11) Authors: Elitsa Y. Dimova, Carine Michiels, Thomas Kietzmann
|
| |
|
|
| |
|
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
|
| |
|
pp.3878-3885 (8) Author: Johanna Myllyharju
|
| |
|
|
| |
|
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
|
| |
|
pp.3886-3894 (9) Authors: Roland H. Wenger, Gieri Camenisch, Daniel P. Stiehl, Dorthe M. Katschinski
|
| |
|
|
| |
|
The VHL Tumor Suppressor: Master Regulator of HIF
|
| |
|
pp.3895-3903 (9) Author: Volker H. Haase
|
| |
|
|
| |
|
Signalling Cross Talk of the HIF System: Involvement of the FIH Protein
|
| |
|
pp.3904-3907 (4) Authors: M. L. Coleman, P. J. Ratcliffe
|
| |
|
|
| |
|
Potential Role of Dental Stem Cells in the Cellular Therapy of Cerebral Ischemia
|
| |
|
pp.3908-3916 (9) Authors: Mehmet E. Yalvac, Albert A. Rizvanov, Ertugrul Kilic, Fikrettin Sahin, Marat A. Mukhamedyarov, Rustem R. Islamov, Andras Palotas
|
| |
|
|
